[Artículo traducido] Gravedad de la psoriasis, calidad de vida relacionada con la salud, productividad laboral y deterioro de la actividad en pacientes con psoriasis moderada a grave que reciben tratamiento sistémico: datos de la vida real de la práctica clínica en España

Puig, 2019, La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en España, Revista Española de Salud Pública, 93, e1 Griffiths, 2018, A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey, Br J Dermatol, 179, 173, 10.1111/bjd.16332 Møller, 2015, A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values, Patient Relat Outcome Meas, 6, 167 Carrascosa, 2022, Actas Dermosifiliogr, 113, 261, 10.1016/j.ad.2021.10.003 Ros, 2014, Cumulative life course impairment: the imprint of psoriasis on the patient's life, Actas Dermosifiliogr, 105, 128, 10.1016/j.ad.2013.02.009 Blair, 2020, Risankizumab: a review in moderate to severe plaque psoriasis, Drugs, 80, 1235, 10.1007/s40265-020-01357-1 Daudén, 2016, Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology, J Eur Acad Dermatol Venereol, 30, 1, 10.1111/jdv.13542 Carretero, 2018, Redefining the therapeutic objective in psoriatic patients candidates for biological therapy, J Dermatolog Treat, 29, 334, 10.1080/09546634.2017.1395794 Mahil, 2020, Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR), Br J Dermatol, 182, 1158, 10.1111/bjd.18333 Amatore, 2019, French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults, J Eur Acad Dermatol Venereol, 33, 464, 10.1111/jdv.15340 Gisondi, 2017, Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis, J Eur Acad Dermatol Venereol, 31, 774, 10.1111/jdv.14114 Mattei, 2014, Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies, J Eur Acad Dermatol Venereol, 28, 333, 10.1111/jdv.12106 Herédi, 2014, Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary, Eur J Health Econ, 15, S111, 10.1007/s10198-014-0600-x Fundación Piel Sana-Academia Española de Dermatología y Venereología (AEDV). BIOBADADERM. Registro Español de acontecimientos adversos de terapias sistémicas en psoriasis; 2020. https://biobadaderm.fundacionpielsana.es/post.aspx?id=236&title=Informe-Biobadaderm-2020. Rivera, 2011, BIOBADADERM, The Spanish Registry of adverse events associated with biologic drugs in dermatology: first report, Actas Dermosifiliogr, 102, 132, 10.1016/j.ad.2010.10.016 de Tiedra, 1998, Adaptación transcultural al español del cuestionario Dermatology Life Quality Index (DLQI): el índice de calidad de vida en dermatología, Actas Dermo-Sifiliogr, 89, 692 Reilly associates. WPAI:PSO (v2.0 Spanish-Spain). http://www.reillyassociates.net/WPAI_Translations.html. Puig, 2014, Predictors of biologic treatment of psoriasis: a non-interventional study, Clinicoecon Outcomes Res, 6, 93 Puig, 2017, A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain, J Eur Acad Dermatol Venereol, 31, 1176, 10.1111/jdv.14195 Sanchez-Carazo, 2014, Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study), J Dermatol, 41, 673, 10.1111/1346-8138.12465 Burgos-Pol, 2016, The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review, Actas Dermo-Sifiliogr (Engl Ed), 107, 577 Gladman, 2005, Psoriatic arthritis: epidemiology, clinical features, course, and outcome, Ann Rheum Dis, 64, ii14 Prodanovich, 2009, Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality, Arch Dermatol, 145, 700, 10.1001/archdermatol.2009.94 Carrascosa, 2015, Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice, J Dermatolog Treat, 26, 502, 10.3109/09546634.2015.1034070 Bagel, 2021, Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data, J Med Econ, 24, 782, 10.1080/13696998.2021.1937187 Feldman, 2017, Economic impact of above-label dosing with etanercept, adalimumab, or ustekinumab in patients with psoriasis, J Manag Care Spec Pharm, 23, 583 Armstrong, 2019, Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies, Am J Clin Dermatol, 20, 155, 10.1007/s40257-018-0396-z Houghton, 2021, Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab, Dermatol Ther (Heidelb), 11, 1373, 10.1007/s13555-021-00564-2 Villacorta, 2020, A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis, Br J Dermatol, 183, 548, 10.1111/bjd.18798 Puig, 2020, Opinion survey on persistence of biologic therapies in patients with moderate to severe psoriasis, Actas Dermosifiliogr (Engl Ed), 111, 691, 10.1016/j.ad.2020.01.001